Cybin Secures Additional U.S. Patent for CYB003

LOS ANGELES- Cybin Inc. a biopharmaceutical company, announced the granting of U.S. patent 12,291,499 by the United States Patent and Trademark Office. This patent pertains to pharmaceutical compositions and oral dosage forms within the company’s CYB003 program, a deuterated psilocin analog currently in Phase 3 development for the adjunctive treatment of Major Depressive Disorder (MDD). The patent is expected to provide exclusivity until at least 2041.

CYB003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA), facilitating an expedited development pathway. The ongoing Phase 3 program, known as PARADIGM, includes two pivotal studies: APPROACH, which has commenced patient dosing, and EMBRACE, anticipated to begin mid-2025. A long-term extension study, EXTEND, is also planned to assess the safety and efficacy of CYB003 over an extended period.

Cybin’s intellectual property portfolio now comprises over 80 granted patents and more than 230 pending applications. The company continues to focus on developing innovative treatment options for mental health conditions, with CYB003 representing a significant component of its pipeline.